Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant. [electronic resource]
Producer: 20190719Description: 159-161 p. digitalISSN:- 1528-3933
- Antineoplastic Agents, Immunological -- therapeutic use
- Child
- Heart Transplantation
- Humans
- Immunosuppressive Agents -- therapeutic use
- Injections, Intraocular
- Iris Neoplasms -- drug therapy
- Lymphoma, B-Cell, Marginal Zone -- drug therapy
- Lymphoproliferative Disorders -- drug therapy
- Male
- Postoperative Complications -- drug therapy
- Rituximab -- therapeutic use
No physical items for this record
Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.